Gastric cancer (GC) is one of the most common malignancies worldwide and it is the fourth
leading cause of cancer-related death. GC is a multifactorial disease, where both …

Gastric cancer is one of the leading causes of cancer-related death worldwide. Many
patients have inoperable disease at diagnosis or have recurrent disease after resection with …

More than 1 million (1 089 103) new cases of gastric cancer were estimated globally in
2020, resulting in 768 793 deaths. 1 These burden estimates will continue to increase due to …

Almost one million (951 600) new cases of gastric cancer were diagnosed globally in 2012,
resulting in∼ 723 100 deaths [1]. Of these∼ 140 000 cases and∼ 107 000 deaths occurred …

Background The CLASSIC trial was done to compare adjuvant capecitabine plus oxaliplatin
versus observation after D2 gastrectomy for patients with stage II or III gastric cancer. The …

Gastric cancer is the fifth most common cancer and the third most common cause of cancer
death globally. Risk factors for the condition include Helicobacter pylori infection, age, high …

The authors focused on the current surgical treatment of resectable gastric cancer, and
significance of peri-and post-operative chemo or chemoradiation. Gastric cancer is the 4 th …

Background D2 gastrectomy is recommended in US and European guidelines, and is
preferred in east Asia, for patients with resectable gastric cancer. Adjuvant chemotherapy …

Purpose After curative resection, the prognosis of gastroesophageal adenocarcinoma is
poor. This phase III trial was designed to evaluate the benefit in overall survival (OS) of …

Purpose The first planned interim analysis (median follow-up, 3 years) of the Adjuvant
Chemotherapy Trial of S-1 for Gastric Cancer confirmed that the oral fluoropyrimidine …